Press Release Source: Entest BioMedical, Inc. On Thursday January 28, 2010, 10:00 am EST SAN DIEGO, CA--(Marketwire - 01/28/10) - Bio-Matrix Scientific Group Inc. (OTC.BB:BMSN - News) announced that its majority owned subsidiary, Entest BioMedical Inc. (OTC.BB:ENTB - News) will be addressing the Company's progress on stem cell / laser therapy for the treatment of COPD on Stem Cell Pioneer's "Ask the Doctor" (www.stemcellpioneers.com).
Stem Cell Pioneers is believed to be one of the largest patient moderated forums online. It is a community of patients, medical professionals and individuals interested in the areas of progress in Stem Cell Therapy across a multitude of diseases. The Company believes participating in forums such as "Ask the Doctor" provide an opportunity to create awareness of COPD and help in the development of public policy regarding its future treatment.
The Company's Chairman & CEO, David Koos, stated "We are excited to be invited to participate in this forum. Since we first announced our intentions to produce a stem cell therapy for the treatment of COPD, we have been inundated with inquiries on our progress. Forums like Stem Cell Pioneers allow us a venue to answer questions, update our progress and get feedback from patients suffering from COPD."
A Company spokesperson noted that COPD will cost $170 billion over the next 5 years just to provide short term relief. "We believe our Stem Cell Laser therapy could reduce this cost dramatically, re-focusing these dollars on actually curing patients."
The Company encourages anyone interested in Entest's participation on this forum to join its Twitter page (http://twitter.com/Entest_BioMed) or email the Company at firstname.lastname@example.org for the exact date of the forum release.
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTC.BB:ENTB - News) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT - 576 is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD.
About Bio-Matrix Scientific Group:
Bio-Matrix Scientific Group Inc. (OTC.BB:BMSN - News) is the majority owner of Entest BioMedical Inc. BMSN is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact: Contact:David R. KoosChairman & CEO619.702.1404 Direct619.330.2328 FaxEntest BioMedical Inc.Email Contactwww.EntestBio.comBio-Matrix Scientific Group Inc.www.BMSN.usEmail ContactFollow the Company's progress on Twitter:http://twitter.com/Entest_BioMed
Posts: 598 | Registered: Mar 2005
| IP: Logged |